


Supplemental Figure 1: Treatment with recombinant human IFN- γ , IL-4 or TNF- α does not impact 25(OH)D₃ to 1,25(OH)₂D₃ metabolism by control HSNEC. *p<0.05 between versus PBS treatment. n=3 cell lines from different individuals.



Supplemental Figure 2: Montelukast and inhibition of the IL-4 receptor fail to block Af suppression of HSNEC 1α-hydroxylase. Control HSNEC were treated concurrently with Af with or without treatment with montelukast or neutralizing antibody to the IL-4 receptor.